University of Texas System

Fred Hutchinson Cancer Center

Immune-onc Therapeutics, Inc.

Fred Hutchinson Cancer Research Center

Mi Deng

Chengcheng Zhang

Zhiqiang An

Ningyan Zhang

Xun Gui

Junke Zheng

Wei Xiong

Qiang Liu

X Charlene Liao

Chuo Chen

Irwin D Bernstein

Jingjing Xie

Yi Liu

Jiawei Liu

Zhigang Lu

Tao Huang

Jaehyup Kim

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

LILRB4 antibodies and uses thereof

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

Methods for identifying LILRB-blocking antibodies

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Anti-LILRB antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.

Compounds supports hematopoietic stem cells and red blood cells

The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.

LILRB2 and notch-mediated expansion of hematopoietic precursor cells

Growing community of inventors

Plano, TX, United States of America

Mi Deng